Actavis Laboratories UT, Inc. was unable to show that patents licensed to Endo Pharmaceuticals Inc. covering its testosterone gel product Fortesta® were invalid as obvious in light of prior art, according to the U.S. Court of Appeals for the Federal Circuit. Therefore, a district court ruling finding that the patents were not obvious was affirmed (Endo Pharmaceuticals Inc. v. Actavis Laboratories UT, Inc., October 14, 2016, Taranto, R.).
A full summary of this case has been published on Kluwer IP Law.
________________________
To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.
